BioXcel Therapeutics Balance Sheet Health
Financial Health criteria checks 2/6
BioXcel Therapeutics has a total shareholder equity of $-56.5M and total debt of $100.6M, which brings its debt-to-equity ratio to -178%. Its total assets and total liabilities are $73.7M and $130.2M respectively.
Key information
-178.0%
Debt to equity ratio
US$100.60m
Debt
Interest coverage ratio | n/a |
Cash | US$65.22m |
Equity | -US$56.51m |
Total liabilities | US$130.21m |
Total assets | US$73.70m |
Recent financial health updates
No updates
Recent updates
BioXcel Therapeutics: Igalmi's Commercial Uncertainty Remains, Downgrading To A Hold
Aug 28BioXcel Therapeutics Q2 2022 Earnings Preview
Aug 08BioXcel Therapeutics: BXCL501 For Acute Agitation In Patients With Dementia And Alzheimer's - A Great Asset
Jul 19BioXcel's Igalmi: Potential Market For Acute Agitation In Esquizofrenia And Bipolar Patients
May 18Financial Position Analysis
Short Term Liabilities: BTAI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BTAI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BTAI has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BTAI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BTAI has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: BTAI is forecast to have sufficient cash runway for 9 months based on free cash flow estimates, but has since raised additional capital.